All In Biotech

Drug Trial Radar · NCT00430248

Efficacy and Safety of Oral Febuxostat in Participants With Gout

A Phase 3, Randomized, Multicenter, Double-Blind, Allopurinol-Controlled Study Assessing the Efficacy and Safety of Oral Febuxostat in Subjects With Gout.

Last checked: Nov 20, 2026Latest source record: Feb 2, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,269 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,269

Actual

Start

Feb 2007

Primary completion

Mar 2008

Study completion Mar 2008

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Feb 1, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy and safety of febuxostat, once Daily (QD), to allopurinol in subjects with hyperuricemia and gout.

Conditions

  • Gout

Interventions

  • FebuxostatDrug

    Febuxostat 40 mg, capsules, orally, once daily for up to 6 months.

  • FebuxostatDrug

    Febuxostat 80 mg, capsules, orally, once daily for up to 6 months.

  • AllopurinolDrug

    Allopurinol 200 mg or 300 mg, capsules, orally, once daily for up to 6 months. Dose is dependent on the subject's renal function. Subjects with normal renal function or mild renal impairment received 300 mg once daily; subjects with moderate renal impairment received 200 mg once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects Whose Serum Urate Level is <6.0 Milligrams Per Deciliter (mg/dL) at the Final Visit.Time frame: Last Visit on treatment (up to 6 months)

Locations

258 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Hoover, Alabama

  • Site not named

    Hueytown, Alabama

  • Site not named

    Huntsville, Alabama

  • Site not named

    Mobile, Alabama

  • Site not named

    Montgomery, Alabama

  • Site not named

    Northport, Alabama

  • Site not named

    Ozark, Alabama

  • Site not named

    Tuscaloosa, Alabama

  • Site not named

    Chandler, Arizona

  • Site not named

    Gilbert, Arizona

  • Site not named

    Mesa, Arizona

  • Site not named

    Peoria, Arizona

  • Site not named

    Phoenix, Arizona

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Sierra Vista, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Fort Smith, Arkansas

  • Site not named

    Jonesboro, Arkansas

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Anaheim, California

  • Site not named

    Carmichael, California

  • Site not named

    Clovis, California

  • Site not named

    Concord, California

  • Site not named

    El Centro, California

  • Site not named

    Fair Oaks, California

  • Site not named

    Fullerton, California

  • Site not named

    Huntington Beach, California

  • Site not named

    Irvine, California

  • Site not named

    La Jolla, California

  • Site not named

    Laguna Hills, California

  • Site not named

    Los Angeles, California

  • Site not named

    Pasadena, California

  • Site not named

    Rancho Cucamonga, California

  • Site not named

    Riverside, California

  • Site not named

    Sacramento, California

  • Site not named

    San Diego, California

  • Site not named

    San Luis Obispo, California

  • Site not named

    Santa Barbara, California

  • Site not named

    Santa Maria, California

Showing 40 of 258 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.